GlassScriptPhysician profile
Tesa Linstad
NPI 1952868713
$7,546.66
in general payments reported to CMS, 2019-2025
40 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $818 · 2023: $2,258 · 2024: $2,770 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,454.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,660.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $597.83 | 2022-2025 | Farxiga, Airsupra |
| Neurelis, INC. | $471.21 | 2022-2025 | Valtoco |
| Argenx US, INC. | $440.74 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $413.56 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $393.12 | 2021-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $343.01 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $296.82 | 2021-2023 | Ongentys, Ingrezza |
| Alexion Pharmaceuticals, INC. | $286.73 | 2024-2025 | Ultomiris |
| Ucb, INC. | $249.03 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Lilly USA, LLC | $228.83 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $225.52 | 2023-2025 | |
| Biogen, INC. | $181.20 | 2022-2025 | Vumerity, Tysabri |
| Sumitomo Pharma America, INC. | $160.97 | 2023 | Aptiom |
| Neuronetics, INC. | $159.22 | 2022-2025 | Neurostar Tms Therapy System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $150.53 | 2023-2024 | Ampyra, Inbrija |
| Sk Life Science, INC. | $145.59 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $145.52 | 2021-2022 | |
| Banner Life Sciences, LLC | $137.16 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.82 | 2024 | Zeposia |
| Celgene Corporation | $91.74 | 2021-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $70.48 | 2023-2025 | Rytary, Crexont |
| Emd Serono, INC. | $62.06 | 2024 | |
| Janssen Pharmaceuticals, INC | $57.33 | 2021-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $47.35 | 2024 | Rexulti |
| Genentech USA, INC. | $46.36 | 2024 | Ocrevus Zunovo, Ocrevus |
| Lundbeck LLC | $45.53 | 2023-2025 | Rexulti, Vyepti |
| Tg Therapeutics, INC. | $44.00 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $38.79 | 2024 | Onpattro, Amvuttra |
| Merz Pharmaceuticals, LLC | $35.43 | 2025 | Inbrija |
| Biohaven Pharmaceuticals, INC. | $25.58 | 2021 | |
| Jazz Pharmaceuticals INC. | $25.03 | 2024 | |
| Acadia Pharmaceuticals INC | $23.09 | 2025 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $19.56 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $19.37 | 2023 | Relyvrio |
| Cala Health, INC. | $17.76 | 2024 | Cala Trio, Cala Kiq |
| Genzyme Corporation | $17.40 | 2022 | |
| Novo Nordisk INC | $16.86 | 2023 | Wegovy |
| Boston Scientific Corporation | $15.14 | 2025 | Vercise |
| Kyowa Kirin, INC. | $14.66 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tesa Linstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.